argenx NV ADR (ARGX)vsPrecision BioSciences Inc (DTIL)
ARGX
argenx NV ADR
$909.50
+5.82%
HEALTHCARE · Cap: $56.45B
DTIL
Precision BioSciences Inc
$7.88
+1.40%
HEALTHCARE · Cap: $204.35M
Smart Verdict
WallStSmart Research — data-driven comparison
argenx NV ADR generates 10422% more annual revenue ($4.74B vs $45.07M). ARGX leads profitability with a 31.4% profit margin vs -96.7%. ARGX earns a higher WallStSmart Score of 73/100 (B).
ARGX
Strong Buy73
out of 100
Grade: B
DTIL
Avoid33
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+62.1%
Fair Value
$2204.33
Current Price
$909.50
$1294.83 discount
Margin of Safety
+72.2%
Fair Value
$14.65
Current Price
$7.88
$6.77 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Keeps 31 of every $100 in revenue as profit
Strong operational efficiency at 30.0%
Revenue surging 62.6% year-over-year
Earnings expanding 114.0% YoY
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Revenue surging 37272.0% year-over-year
Reasonable price relative to book value
Areas to Watch
Weak financial health signals
Premium valuation, high expectations priced in
Trading at 192.3x book value
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -58.5% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : ARGX
The strongest argument for ARGX centers on Profit Margin, Operating Margin, Revenue Growth. Profitability is solid with margins at 31.4% and operating margin at 30.0%. Revenue growth of 62.6% demonstrates continued momentum.
Bull Case : DTIL
The strongest argument for DTIL centers on Revenue Growth, Price/Book. Revenue growth of 37272.0% demonstrates continued momentum.
Bear Case : ARGX
The primary concerns for ARGX are Piotroski F-Score, P/E Ratio, Price/Book. A P/E of 40.2x leaves little room for execution misses.
Bear Case : DTIL
The primary concerns for DTIL are EPS Growth, Market Cap, Piotroski F-Score.
Key Dynamics to Monitor
ARGX profiles as a growth stock while DTIL is a hypergrowth play — different risk/reward profiles.
DTIL carries more volatility with a beta of 1.28 — expect wider price swings.
DTIL is growing revenue faster at 37272.0% — sustainability is the question.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ARGX scores higher overall (73/100 vs 33/100), backed by strong 31.4% margins and 62.6% revenue growth. DTIL offers better value entry with a 72.2% margin of safety. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
argenx NV ADR
HEALTHCARE · BIOTECHNOLOGY · USA
argenx SE, a clinical-phase biotechnology company, focuses on the development of antibody-based therapies for the treatment of autoimmune diseases, hematology and cancer. The company is headquartered in Breda, the Netherlands.
Precision BioSciences Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Precision BioSciences, Inc., a genome editing company, develops therapeutic products in the United States. The company is headquartered in Durham, North Carolina.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?